Maxigen Biotech Inc. (1783.TW)
TWD 41.1
(-1.2%)
TWD 41.1
(-1.2%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 50 Thousand TWD | 0.0% |
| 2022 | - TWD | -100.0% |
| 2021 | 9.74 Million TWD | -19.72% |
| 2020 | 12.13 Million TWD | -17.41% |
| 2019 | 14.69 Million TWD | -93.11% |
| 2018 | 213.23 Million TWD | 1333.2% |
| 2017 | 14.87 Million TWD | -9.74% |
| 2016 | 16.48 Million TWD | -76.8% |
| 2015 | 71.04 Million TWD | -8.65% |
| 2014 | 77.76 Million TWD | -2.79% |
| 2013 | 80 Million TWD | -0.06% |
| 2012 | 80.04 Million TWD | 0.06% |
| 2011 | 80 Million TWD | 1143.97% |
| 2010 | 6.43 Million TWD | -30.75% |
| 2009 | 9.28 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 509 Thousand TWD | 918.0% |
| 2024 Q1 | 50 Thousand TWD | 0.0% |
| 2023 Q3 | 50 Thousand TWD | 0.0% |
| 2023 Q2 | - TWD | 0.0% |
| 2023 FY | 50 Thousand TWD | 0.0% |
| 2023 Q1 | - TWD | 0.0% |
| 2023 Q4 | 50 Thousand TWD | 0.0% |
| 2022 Q2 | - TWD | -100.0% |
| 2022 Q1 | 9.05 Million TWD | -7.04% |
| 2022 FY | - TWD | -100.0% |
| 2022 Q4 | - TWD | 0.0% |
| 2022 Q3 | - TWD | 0.0% |
| 2021 Q3 | 10.24 Million TWD | -5.42% |
| 2021 Q4 | 9.74 Million TWD | -4.91% |
| 2021 Q1 | 11.57 Million TWD | -4.62% |
| 2021 FY | 9.74 Million TWD | -19.72% |
| 2021 Q2 | 10.83 Million TWD | -6.42% |
| 2020 Q4 | 12.13 Million TWD | -5.01% |
| 2020 FY | 12.13 Million TWD | -17.41% |
| 2020 Q1 | 14.05 Million TWD | -4.36% |
| 2020 Q2 | 13.4 Million TWD | -4.57% |
| 2020 Q3 | 12.77 Million TWD | -4.74% |
| 2019 Q1 | 16.61 Million TWD | -92.2% |
| 2019 Q2 | 15.98 Million TWD | -3.84% |
| 2019 Q3 | 15.32 Million TWD | -4.09% |
| 2019 Q4 | 14.69 Million TWD | -4.16% |
| 2019 FY | 14.69 Million TWD | -93.11% |
| 2018 Q3 | 3000.00 TWD | -99.98% |
| 2018 Q1 | 14.47 Million TWD | -2.74% |
| 2018 FY | 213.23 Million TWD | 1333.2% |
| 2018 Q4 | 213.13 Million TWD | 7104400.0% |
| 2018 Q2 | 14.09 Million TWD | -2.61% |
| 2017 Q4 | 14.87 Million TWD | -2.64% |
| 2017 Q2 | 15.68 Million TWD | -2.49% |
| 2017 Q1 | 16.08 Million TWD | -2.42% |
| 2017 FY | 14.87 Million TWD | -9.74% |
| 2017 Q3 | 15.28 Million TWD | -2.56% |
| 2016 Q2 | 67.96 Million TWD | -2.22% |
| 2016 Q1 | 69.51 Million TWD | -2.15% |
| 2016 FY | 16.48 Million TWD | -76.8% |
| 2016 Q4 | 16.48 Million TWD | -2.31% |
| 2016 Q3 | 16.87 Million TWD | -75.17% |
| 2015 Q3 | 72.58 Million TWD | -2.0% |
| 2015 FY | 71.04 Million TWD | -8.65% |
| 2015 Q4 | 71.04 Million TWD | -2.12% |
| 2015 Q2 | 74.06 Million TWD | -2.13% |
| 2015 Q1 | 75.67 Million TWD | -2.69% |
| 2014 Q1 | 80.01 Million TWD | 0.02% |
| 2014 Q4 | 77.76 Million TWD | -1.87% |
| 2014 FY | 77.76 Million TWD | -2.79% |
| 2014 Q3 | 79.24 Million TWD | -1.82% |
| 2014 Q2 | 80.71 Million TWD | 0.88% |
| 2013 FY | 80 Million TWD | -0.06% |
| 2013 Q2 | 80.12 Million TWD | 0.0% |
| 2013 Q3 | 80.12 Million TWD | 0.0% |
| 2013 Q4 | 80 Million TWD | -0.15% |
| 2013 Q1 | - TWD | -100.0% |
| 2012 Q4 | 80.04 Million TWD | 0.0% |
| 2012 FY | 80.04 Million TWD | 0.06% |
| 2012 Q2 | 80.1 Million TWD | 0.0% |
| 2011 Q2 | 81.45 Million TWD | 0.0% |
| 2011 Q4 | 80 Million TWD | 0.0% |
| 2011 FY | 80 Million TWD | 1143.97% |
| 2010 Q4 | 6.43 Million TWD | 0.0% |
| 2010 FY | 6.43 Million TWD | -30.75% |
| 2009 FY | 9.28 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 605.96 Million TWD | 99.992% |
| SciVision Biotech Inc. | 347.91 Million TWD | 99.986% |
| Bionime Corporation | 2.81 Billion TWD | 99.998% |
| Pegavision Corporation | 1.56 Billion TWD | 99.997% |
| Visco Vision Inc. | 1.08 Billion TWD | 99.995% |